General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Medtronic PLC (MDT) Is a Trending Stock: Facts to Know Before Betting on It | zacks.com • |
Medtronic PLC (MDT) Is a Trending Stock: Facts to Know Before Betting on It | news.google.com • |
Medtronic plc (NYSE:MDT) Shares Sold by Sigma Planning Corp | news.google.com • |
Tennessee Valley Asset Management Partners Takes Position in Medtronic plc (NYSE:MDT) | news.google.com • |
Medtronic PLC stock rises Tuesday, still underperforms market | news.google.com • |
Medical AI Could Be Your Ticket to Riches: 3 Stocks to Buy | investorplace.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-23 | 2024-04 | 1.45 | N/A | N/A | N/A |
2024-02-20 | 2024-01 | 1.26 | 1.3 | 0.04 | 3.17% |
2023-11-21 | 2023-10 | 1.18 | 1.25 | 0.07 | 5.93% |
2023-08-22 | 2023-07 | 1.11 | 1.2 | 0.09 | 8.11% |
2023-05-25 | 2023-04 | 1.56 | 1.57 | 0.01 | 0.64% |
2023-02-21 | 2023-01 | 1.26 | 1.3 | 0.04 | 3.17% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-08-22 | Stifel | Upgrade | Buy | Buy |
2023-08-22 | Wells Fargo | Upgrade | Overweight | Overweight |
2023-08-22 | Mizuho | Upgrade | Buy | Buy |
2023-08-22 | UBS | Upgrade | Sell | Sell |
2023-08-22 | Oppenheimer | Upgrade | Perform | Perform |
2023-08-22 | RBC Capital | Upgrade | Sector Perform | Sector Perform |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2023-07-30 | FONG IVAN K | General Counsel | 40.81K | Stock Award(Grant) |
2023-08-02 | KIRK JENNIFER M | Officer | 14.19K | Conversion of Exercise of derivative security |
2024-04-07 | MARINARO MICHAEL | Officer | 27.93K | Sale |
2023-08-02 | MARTHA GEOFFREY S | Chief Executive Officer | 141.14K | Stock Award(Grant) |
2023-08-02 | PARKHILL KAREN L | Chief Financial Officer | 98.72K | Stock Award(Grant) |
2024-02-20 | SALMON SEAN M | Officer | 48.29K | Sale |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Group Inc | 125.84M | 11.09B | 9.46% |
2023-06-29 | Blackrock Inc. | 114.95M | 10.13B | 8.64% |
2023-06-29 | State Street Corporation | 60.15M | 5.30B | 4.52% |
2023-06-29 | Massachusetts Financial Services Co. | 36.00M | 3.17B | 2.71% |
2023-06-29 | Capital Research Global Investors | 31.49M | 2.77B | 2.37% |
2023-06-29 | Geode Capital Management, LLC | 25.62M | 2.26B | 1.93% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 41.50M | 3.66B | 3.12% |
2023-06-29 | Vanguard 500 Index Fund | 31.68M | 2.79B | 2.38% |
2023-05-30 | Fidelity 500 Index Fund | 14.88M | 1.23B | 1.12% |
2023-08-30 | SPDR S&P 500 ETF Trust | 14.64M | 1.19B | 1.10% |
2023-08-30 | iShares Core S&P 500 ETF | 12.44M | 1.01B | 0.94% |
2023-07-30 | Vanguard Specialized-Dividend Growth Fund | 12.09M | 1.06B | 0.91% |
Dividend | Date |
---|---|
0.69 | 2024-03-22 |
0.69 | 2024-03-21 |
0.69 | 2023-12-20 |
0.69 | 2023-12-19 |
0.69 | 2023-09-21 |
0.69 | 2023-06-22 |
Split | Date |
---|---|
2 : 1 | 1999-09-27 |
2 : 1 | 1997-09-15 |
2 : 1 | 1995-09-29 |
2 : 1 | 1994-09-30 |
2 : 1 | 1991-08-30 |
2 : 1 | 1989-08-31 |
How many knew that Ocugen had a partnership which contractually GUARANTEES them revenues from Covid19 Antibody Testing?
(re: page 22 of annual report):
https://www.sec.gov/Archives/edgar/data/1372299/000110465920053502/tm2017927-1_10ka.htm
Collaboration with Advaite, Inc.
In April 2020, the Company entered into an agreement with Advaite, Inc., (Advaite) to provide certain support services for Advaite's development of a diagnostic test kit that is designed to detect antibodies to COVID-19. ...{Ocugen}... will receive tiered royalty payments based on cumulative net sales of the test kit.
The projected market for Covid diagnostic testing is $61B AND GROWING!
MORE IMPORTANTLY Advaite is NOW MOVING on Covid Antibody Testing!
https://www.linkedin.com/mwlite/company/advaite
*
The BEAUTY here:
NOBODY KNOWS Ocugen will be collecting potentially BILLION$ in COVID DIAGNOSTICS revenue! They NEVER did a PRESS RELEASE!
$SAVA - A second opinion
*
If you have been following Cassava and their Alzheimers drug PTI-125, you will know that 1 of 2 trial endpoints was not recently met, sending the stock down almost 80%. But, I think the exodus was premature. Here is why:
Per the companys press release, one endpoint WAS MET:
A secondary endpoint of CSF levels of IL1-beta, a core biomarker of neuroinflammation from baseline to day 28, was met, Cassava said. The drug was also found to be safe and well-tolerated.
Per NIH, neuro inflammation is the CORE issue with Alzheimers:
Inflammation in Alzheimer's disease (AD) has emerged as a central pathology that likely plays a role in onset and progression of the disease
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214864/
Cycling back to Cassavas press release, they state:
CSF levels of IL1-beta, a core biomarker of neuroinflammation ... was met
To reiterate the NIH definition, Neuro Inflammation is core to the onset and progression of Alzheimers. At some point, Cassava IS going to cycle back around to the secondary endpoint (neuro inflammation), and realize that ALONE constitutes an ALZHEIMER DRUG THAT WORKS.
In this case, traders were SO tuned into the word miss that they MISSED something EXTREMELY IMPORTANT -> The efficacy of PTI-125 towards Neuro Inflammation, in Alzheimers (ALONE), makes it A BLOCKBUSTER DRUG!
$SAVA - A second opinion
*
If you have been following Cassava and their Alzheimers drug PTI-125, you will know that 1 of 2 trial endpoints was not recently met, sending the stock down almost 80%. But, I think the exodus was premature. Here is why:
Per the companys press release, one endpoint WAS MET:
A secondary endpoint of CSF levels of IL1-beta, a core biomarker of neuroinflammation from baseline to day 28, was met, Cassava said. The drug was also found to be safe and well-tolerated.
Per NIH, neuro inflammation is the CORE issue with Alzheimers:
Inflammation in Alzheimer's disease (AD) has emerged as a central pathology that likely plays a role in onset and progression of the disease
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214864/
Cycling back to Cassavas press release, they state:
CSF levels of IL1-beta, a core biomarker of neuroinflammation ... was met
To reiterate the NIH definition, Neuro Inflammation is core to the onset and progression of Alzheimers. At some point, Cassava IS going to cycle back around to the secondary endpoint (neuro inflammation), and realize that ALONE constitutes an ALZHEIMER DRUG THAT WORKS.
In this case, traders were SO tuned into the word miss that they MISSED something EXTREMELY IMPORTANT - The efficacy of PTI-125 towards Neuro Inflammation, in Alzheimers (ALONE), makes it A BLOCKBUSTER DRUG!